Vertex Pharmaceuticals Incorporated

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1989-01-01

Employees: 5.4K

Market Cap: $123.9B

Website: http://www.vrtx.com

Clinical Trials

A Phase 1, First-in-human Study of VX-634

Phase 1

Completed

Conditions: Alpha 1-Antitrypsin Deficiency

Interventions: Drug: VX-634
Drug: Placebo

First Posted Date: 2022-10-13

Last Posted Date: 2024-03-12

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 127

Registration Number: NCT05579431

Locations: 🇺🇸
Central Florida Pulmonary Group, P.A., Orlando, Florida, United States
🇺🇸
ICON Lenexa, Lenexa, Kansas, United States
🇺🇸
ICON Salt Lake City, Salt Lake City, Utah, United States

and more 2 locations

Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Mild or Moderate Hepatic Impairment

Phase 1

Completed

Conditions: Pain

Interventions: Drug: VX-548

First Posted Date: 2022-09-29

Last Posted Date: 2024-03-20

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 36

Registration Number: NCT05560464

Locations: 🇺🇸
Division of Clinical Pharmacology, University of Miami, Miami, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Oklahoma, United States

Evaluation of Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty

Phase 3

Completed

Conditions: Acute Pain

Interventions: Drug: HB/APAP
Drug: VX-548
Drug: Placebo (matched to VX-548)
Drug: Placebo (matched to HB/APAP)

First Posted Date: 2022-09-28

Last Posted Date: 2024-08-27

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 1118

Registration Number: NCT05558410

Locations: 🇺🇸
Arizona Research Center, Phoenix, Arizona, United States
🇺🇸
Shoals Medical Trials Inc., Sheffield, Alabama, United States
🇺🇸
Endeavor Clinical Trials, San Antonio, Texas, United States

and more 9 locations

Evaluation of Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy

Phase 3

Completed

Conditions: Acute Pain

Interventions: Drug: Placebo (matched to VX-548)
Drug: VX-548
Drug: HB/APAP
Drug: Placebo (matched to HB/APAP)

First Posted Date: 2022-09-23

Last Posted Date: 2024-12-16

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 1075

Registration Number: NCT05553366

Locations: 🇺🇸
Kansas Spine and Specialty Hospital, Wichita, Kansas, United States
🇺🇸
Midwest Clinical Research Center, Dayton, Ohio, United States
🇺🇸
Futuro Clinical Trials, McAllen, Texas, United States

and more 17 locations

A Study to Evaluate the Pharmacokinetic Drug-drug Interactions Between VX-548, Midazolam, and Digoxin

Phase 1

Completed

Conditions: Pain

Interventions: Drug: VX-548
Drug: Midazolam
Drug: Digoxin

First Posted Date: 2022-09-15

Last Posted Date: 2024-03-20

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 37

Registration Number: NCT05541471

Locations: 🇺🇸
Baltimore - Early Phase Clinical Unit, Baltimore, Maryland, United States

A Study to Evaluate the Relative Bioavailability of a Fixed-dose Combination Tablet of VX-121/Tezacaftor/Deutivacaftor

Phase 1

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: VX-121/TEZ/D-IVA

First Posted Date: 2022-09-10

Last Posted Date: 2022-12-12

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 16

Registration Number: NCT05535959

Locations: 🇺🇸
ICON Salt Lake City, Salt Lake City, Utah, United States

A Phase 1 Dose Escalation Study of VX-708 in Healthy Participants

Phase 1

Completed

Conditions: Pain

Interventions: Drug: VX-708
Drug: Placebo
Drug: Midazolam
Drug: Itraconazole

First Posted Date: 2022-08-29

Last Posted Date: 2023-03-30

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 64

Registration Number: NCT05518734

Locations: 🇺🇸
Celerion - Tempe, Tempe, Arizona, United States

Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease

Phase 3

Recruiting

Conditions: Thalassemia
Genetic Diseases, Inborn
Hemoglobinopathies
Beta-Thalassemia
Hematologic Diseases
Sickle Cell Anemia
Sickle Cell Disease

Interventions: Biological: CTX001

First Posted Date: 2022-07-28

Last Posted Date: 2024-05-16

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 26

Registration Number: NCT05477563

Locations: 🇮🇹
Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy
🇸🇦
King Faisal Specialist Hospital and Research Centre, Al Mathar Ash Shamali, Saudi Arabia
🇺🇸
SCRI at the Children's Hospital at TriStar Centennial, Nashville, Tennessee, United States

and more 3 locations

A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-548

Phase 1

Completed

Conditions: Pain

Interventions: Drug: VX-548

First Posted Date: 2022-07-13

Last Posted Date: 2024-03-20

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 24

Registration Number: NCT05455502

Locations: 🇺🇸
ICON Salt Lake City, Salt Lake City, Utah, United States

A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

Phase 3

Active, not recruiting

Conditions: Cystic Fibrosis

Interventions: Drug: VX-121/TEZ/D-IVA

First Posted Date: 2022-07-05

Last Posted Date: 2024-08-13

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 822

Registration Number: NCT05444257

Locations: 🇺🇸
Indiana University, Indianapolis, Indiana, United States
🇺🇸
Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana, United States
🇨🇦
St. Paul's Hospital, Vancouver, Canada

and more 192 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy